Fusion Antibodies PLC Cash Flow Conversion Efficiency

Latest as of September 2025: -0.792x

Fusion Antibodies PLC cash flow conversion efficiency. Based on the latest financial reports, Fusion Antibodies PLC (FAB) has a cash flow conversion efficiency ratio of -0.792x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-575.00K ≈ $-69.96 USD) by net assets (GBX726.00K ≈ $88.33 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Fusion Antibodies PLC (2015–2025)

Cash flow conversion efficiency of Fusion Antibodies PLC from 2015 to 2025. This chart illustrates how Fusion Antibodies PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Fusion Antibodies PLC for real-time trading data and today's change.

Fusion Antibodies PLC Cash Flow Conversion Ratio Explained

Fusion Antibodies PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Fusion Antibodies PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Fusion Antibodies PLC ranked by their cash flow conversion efficiency. Also see FAB market cap for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Itim Group PLC LSE:ITIM	0.123x
Tower Resources plc LSE:TRP	0.068x
abrdn Property Income Trust Ltd. LSE:API	0.916x
Transense Technologies PLC LSE:TRT	0.056x
Goldstone Resources Ltd LSE:GRL	0.097x
Landore Resources Plc LSE:LND	-1.772x
BENO Holding AG XETRA:BENH	N/A
Lion Group Holding Ltd NASDAQ:LGHL	-0.097x

Annual Cash Flow Conversion Efficiency for Fusion Antibodies PLC (2015–2025)

The table below shows the annual cash flow conversion efficiency of Fusion Antibodies PLC from 2015 to 2025. Review cash generation quality of Fusion Antibodies PLC to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	GBX669.00K ≈ $81.40	GBX-1.36 Million ≈ $-165.96	-2.039x	-106.65%
2024-03-31	GBX1.79 Million ≈ $218.16	GBX-1.77 Million ≈ $-215.24	-0.987x	+36.87%
2023-03-31	GBX1.12 Million ≈ $136.64	GBX-1.75 Million ≈ $-213.53	-1.563x	-1644.63%
2022-03-31	GBX3.68 Million ≈ $448.24	GBX-330.00K ≈ $-40.15	-0.090x	+63.06%
2021-03-31	GBX4.75 Million ≈ $577.57	GBX-1.15 Million ≈ $-140.04	-0.242x	-602.87%
2020-03-31	GBX4.81 Million ≈ $585.48	GBX-166.00K ≈ $-20.20	-0.034x	+83.18%
2019-03-31	GBX5.35 Million ≈ $651.44	GBX-1.10 Million ≈ $-133.64	-0.205x	-1847.36%
2018-03-31	GBX6.58 Million ≈ $800.00	GBX77.19K ≈ $9.39	0.012x	+153.59%
2017-03-31	GBX1.71 Million ≈ $207.56	GBX-37.37K ≈ $-4.55	-0.022x	-109.21%
2016-03-31	GBX1.46 Million ≈ $177.28	GBX346.57K ≈ $42.17	0.238x	+122.12%
2015-03-31	GBX169.29K ≈ $20.60	GBX-182.05K ≈ $-22.15	-1.075x	--

About Fusion Antibodies PLC

LSE:FAB UK Biotechnology

Market Cap

$72.60K

GBX596.70 Million GBX

Market Cap Rank

#31607 Global

#1154 in UK

Share Price

GBX5.25

Change (1 day)

-8.70%

52-Week Range

GBX5.25 - GBX19.25

All Time High

GBX213.00